View in EDS HTML Full Text PDF Full Text

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.

Saved in:
Bibliographic Details
Title: A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.
Authors: Mooradian MJ; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Reuben A; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Prieto PA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Hazar-Rethinam M; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Frederick DT; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA., Nadres B; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Piris A; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Massachusetts General Hospital, Boston, MA., Juneja V; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA.; Harvard University and Massachusetts Institute of Technology, Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA.; Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA., Cooper ZA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Sharpe AH; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA.; Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA., Corcoran RB; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Flaherty KT; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Lawrence DP; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Wargo JA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Sullivan RJ; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Source: Oncoimmunology [Oncoimmunology] 2018 Feb 01; Vol. 7 (5), pp. e1423172. Date of Electronic Publication: 2018 Feb 01 (Print Publication: 2018).
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Print ISSN: 2162-4011 (Print) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 29721378
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Mooradian+MJ%22">Mooradian MJ</searchLink>; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Reuben+A%22">Reuben A</searchLink>; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Prieto+PA%22">Prieto PA</searchLink>; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Hazar-Rethinam+M%22">Hazar-Rethinam M</searchLink>; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Frederick+DT%22">Frederick DT</searchLink>; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Nadres+B%22">Nadres B</searchLink>; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Piris+A%22">Piris A</searchLink>; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Massachusetts General Hospital, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Juneja+V%22">Juneja V</searchLink>; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA.; Harvard University and Massachusetts Institute of Technology, Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA.; Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Cooper+ZA%22">Cooper ZA</searchLink>; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Sharpe+AH%22">Sharpe AH</searchLink>; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA.; Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Corcoran+RB%22">Corcoran RB</searchLink>; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Flaherty+KT%22">Flaherty KT</searchLink>; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Lawrence+DP%22">Lawrence DP</searchLink>; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Wargo+JA%22">Wargo JA</searchLink>; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Sullivan+RJ%22">Sullivan RJ</searchLink>; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101570526%22">Oncoimmunology</searchLink> [Oncoimmunology] 2018 Feb 01; Vol. 7 (5), pp. e1423172. <i>Date of Electronic Publication: </i>2018 Feb 01 (<i>Print Publication: </i>2018).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101570526 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2162-4011 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221624011%22">21624011 </searchLink><i>NLM ISO Abbreviation: </i>Oncoimmunology <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=29721378
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/2162402X.2017.1423172
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e1423172
    Titles:
      – TitleFull: A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Mooradian MJ
      – PersonEntity:
          Name:
            NameFull: Reuben A
      – PersonEntity:
          Name:
            NameFull: Prieto PA
      – PersonEntity:
          Name:
            NameFull: Hazar-Rethinam M
      – PersonEntity:
          Name:
            NameFull: Frederick DT
      – PersonEntity:
          Name:
            NameFull: Nadres B
      – PersonEntity:
          Name:
            NameFull: Piris A
      – PersonEntity:
          Name:
            NameFull: Juneja V
      – PersonEntity:
          Name:
            NameFull: Cooper ZA
      – PersonEntity:
          Name:
            NameFull: Sharpe AH
      – PersonEntity:
          Name:
            NameFull: Corcoran RB
      – PersonEntity:
          Name:
            NameFull: Flaherty KT
      – PersonEntity:
          Name:
            NameFull: Lawrence DP
      – PersonEntity:
          Name:
            NameFull: Wargo JA
      – PersonEntity:
          Name:
            NameFull: Sullivan RJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2018 Feb 01
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-print
              Value: 2162-4011
          Numbering:
            – Type: volume
              Value: 7
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Oncoimmunology
              Type: main
ResultId 1